Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Doocey RT, et al. Among authors: lavoie jc. Br J Haematol. 2005 Oct;131(2):223-30. doi: 10.1111/j.1365-2141.2005.05755.x. Br J Haematol. 2005. PMID: 16197454 Free article.
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.
Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJ, Nevill TJ. Lavoie JC, et al. Blood. 2005 Aug 15;106(4):1473-8. doi: 10.1182/blood-2004-12-4689. Epub 2005 May 3. Blood. 2005. PMID: 15870180 Free article.
High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM. Forrest DL, et al. Among authors: lavoie jc. J Clin Oncol. 2005 Nov 1;23(31):7994-8002. doi: 10.1200/JCO.2005.01.9083. Epub 2005 Oct 3. J Clin Oncol. 2005. PMID: 16204014
Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide.
Johny A, Song KW, Nantel SH, Lavoie JC, Toze CL, Hogge DE, Forrest DL, Sutherland HJ, Le A, Nitta JY, Barnett MJ, Smith CA, Shepherd JD, Nevill TJ. Johny A, et al. Among authors: lavoie jc. Biol Blood Marrow Transplant. 2006 Apr;12(4):480-9. doi: 10.1016/j.bbmt.2005.12.031. Biol Blood Marrow Transplant. 2006. PMID: 16545732 Free article.
Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW. Kuruvilla J, et al. Among authors: lavoie jc. Biol Blood Marrow Transplant. 2007 Aug;13(8):925-31. doi: 10.1016/j.bbmt.2007.04.006. Epub 2007 May 29. Biol Blood Marrow Transplant. 2007. PMID: 17640596 Free article. Clinical Trial.
IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Nevill TJ, Shepherd JD, Sutherland HJ, Abou Mourad YR, Lavoie JC, Barnett MJ, Nantel SH, Toze CL, Hogge DE, Forrest DL, Song KW, Power MM, Nitta JY, Dai Y, Smith CA. Nevill TJ, et al. Among authors: lavoie jc. Biol Blood Marrow Transplant. 2009 Feb;15(2):205-13. doi: 10.1016/j.bbmt.2008.11.015. Biol Blood Marrow Transplant. 2009. PMID: 19167680 Free article.
Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.
Lin Y, Bruyère H, Horsman DE, Pantzar T, Barnett MJ, Hogge DE, Nevill TJ, Nantel SH, Sutherland HJ, Toze CL, Shepherd JD, Lavoie JC, Song KW, Smith CA, Forrest DL. Lin Y, et al. Among authors: lavoie jc. Cancer Genet Cytogenet. 2006 Oct 1;170(1):16-23. doi: 10.1016/j.cancergencyto.2006.04.012. Cancer Genet Cytogenet. 2006. PMID: 16965950
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.
Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ, Shepherd JD, Nantel SH, Toze CL, Sutherland HJ, Song KW, Lavoie JC, Power MM, Abou-Mourad Y, Smith CA. Forrest DL, et al. Among authors: lavoie jc. Leuk Res. 2009 Feb;33(2):271-5. doi: 10.1016/j.leukres.2008.07.015. Epub 2008 Aug 31. Leuk Res. 2009. PMID: 18762338
135 results